Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden

July 2012
Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1
Academic Journal
The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti VEGF treatment is the refractory component of neovasculature that resists sustained effects of the treatment.


Related Articles

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • Combining anti-PDGF, anti-VEGF potential next step in stalling wet AMD progression. Hasson, Matt // Ocular Surgery News;2/25/2013, Vol. 31 Issue 4, p32 

    The article reports that anti platelet derived growth factor (anti-PDGF) and anti vascular endothelial growth factor (anti-VEGF) which show that both combination treatments arms meet the pre-specified primary endpoint of superiority.

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Inhibiting VEGF and PDGF to Treat AMD. Mones, Jordi // Review of Ophthalmology;Sep2011, Vol. 18 Issue 9, p56 

    The article discusses the use of anti-vascular endothelial growth factor (Anti-VEGF) agents and platelet-derived growth factor (PDGF) antagonists in treating age-related macular degeneration (AMD). It notes that anti-VEGF agents enhances the vision of patients with wet AMD. It cites that the...

  • VMA does not affect visual acuity after anti-VEGF injections for polypoidal choroidal vasculopathy. Kronemyer, Bob // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p26 

    The article reports that posterior vitreomacular adhesion (VMA) was not associated with visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopath based on a study led by ophthalmologist Dr. Han Joo Cho. Topics discussed include...

  • Erythropoietin slows progressive geographic atrophy in dry AMD eyes. Harrison, Laird // Ophthalmology Times;Oct2015, Vol. 40 Issue 16, p50 

    The article discusses the ability of erythropoietin to slow down the progression of geographic atrophy in patients with age-related macular degeneration (AMD). Topics covered include the impact of the medicine on hindering vision loss in patients with the health condition. Also mentioned is the...

  • OPTIMAL MANAGEMENT OF NEOVASCULAR AMD: WHEN TO TREAT? WHAT TO TREAT? HOW TO TREAT?  // Johns Hopkins Advanced Studies in Ophthalmology;Nov2013, Vol. 10 Issue 3, p57 

    An introduction is presented in which the author discusses the advancement in diagnostic imaging and the strategies for treating age-related macular degeneration (AMD).

  • Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. Batioglu, Figen; Demirel, Sibel; Ă–zmert, Emin; Abdullayev, Ahmet; Bilici, Serdar // BMC Ophthalmology;2015, Vol. 15 Issue 1, p1 

    Background: To investigate the short-term outcomes of treatment with intravitreal aflibercept in cases with wet age-related macular degeneration (AMD) resistant to ranibizumab. Methods: The study included patients who had been undergoing follow-up for a minimum of three months at the Ankara...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics